KBI Biopharma to Open $150 Million Commercial Manufacturing Facility in North Carolina
Set to be operational by the first quarter of 2022, the 140,000-ft2 facility will feature up to six 2000-L, single-use bioreactor systems along with additional harvest and purification equipment to produce up to 100 commercial batches annually.
KBI Biopharma, a JSR Life Sciences company, announced on Dec. 1, 2020 that it has opened a new $150 million commercial manufacturing facility in Research Triangle Park, NC.
Set to be operational by the first quarter of 2022, the 140,000-ft2 facility will feature up to six 2000-L, single-use bioreactor systems along with additional harvest and purification equipment to produce up to 100 commercial batches annually, a company press release said. The new site will also be equipped to provide accommodations for mammalian-based biologics manufacturing processes for KBI’s future and existing collaborators.
“Expansion of our US-based cell culture operations is a key investment to support our client’s commercialization strategies,” said KBI president and CEO Dirk Lange in the press release. “This state-of-the-art facility will leverage the latest innovation in automation and digitalization to best meet the needs for our clients.”
Source: KBI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
